Temodar fails in large Phase III trial in melanoma
This article was originally published in Scrip
Executive Summary
Schering-Plough's brain cancer chemotherapy drug Temodar (temozolomide) has failed to prolong overall survival compared with standard dacarbazine (DTIC) chemotherapy in advanced melanoma in a large Phase III trial.